PFS2 had an HR of 0.75 [95% CI, 0.58-0.98; P = .03], so there's still a major difference between amivantamab [Rybrevant] and lazertinib [Lazcluze] vs osimertinib [Tagrisso], with 72% PFS2 free at 2 ...

The rate of cancer treatment-related cardiac events was 14.9% in patients who received osimertinib and 4.4% in patients who received other EGFR tyrosine kinase inhibitors. Patients with EGFR ...

Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current ...